Abstract:Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the ubiquitin–proteasome system (UPS) in a cyclic catalytic manner. Despite recent endeavors to advance the utilization of PROTACs in clinical settings, the majority of PROTACs fail to progress beyond the preclinical phase of drug development. There are multiple factors impeding the market entry of PROTACs, with the insufficiently precise degradation of favorable POIs standing out as one of the most formidable obstacles. Recently, there has been exploration of new-generation advanced PROTACs, including small-molecule PROTAC prodrugs, biomacromolecule-PROTAC conjugates, and nano-PROTACs, to improve the in vivo efficacy of PROTACs. These improved PROTACs possess the capability to mitigate undesirable physicochemical characteristics inherent in traditional PROTACs, thereby enhancing their targetability and reducing off-target side effects. The new-generation of advanced PROTACs will mark a pivotal turning point in the realm of targeted protein degradation. In this comprehensive review, we have meticulously summarized the state-of-the-art advancements achieved by these cutting-edge PROTACs, elucidated their underlying design principles, deliberated upon the prevailing challenges encountered, and provided an insightful outlook on future prospects within this burgeoning field.

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

World Medical Association ;now more realistic' in dealing with problems.

An overview of PROTACs: a promising drug discovery paradigm

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

PROTACs in gastrointestinal cancers

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Distribution patterns of metastases in recurrent laryngeal nerve lymph nodes in patients with squamous cell esophageal cancer.

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Developments of PROTACs technology in immune-related diseases

PROTACs: A novel strategy for cancer therapy

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Strain difference of murine bone marrow‐derived mast cell functions

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges